Hadassah

Drug May Prevent Recurrence of Aggressive Cancer

Tuesday, Jun 20 2017

New Study led by Hadassah Hospital Oncologist Dr. Amir Sonnenblick

An international team led by Hadassah Hospital Oncologist Dr. Amir Sonnenblick reveals that giving a drug called metformin to diabetic women with a particularly aggressive form of breast cancer may prevent its recurrence.

This HER2-positive breast cancer tends to grow faster, is more likely to spread, and is more likely to come back, as compared with HER2-negative breast cancers. When insulin is given to HER2-positive patients, the treatment doubles their risk of cancer recurrence.

Previous studies have suggested that administering metformin, an anti-diabetic drug that primarily suppresses glucose production by the liver, may prevent or delay recurrence of breast cancer. Dr. Sonnenblick’s study, which was based on a very large database from a Phase III clinical trial, involved over 8,381 breast cancer patients from around the world. While 7,935 of the patients (94.7 percent) had no history of diabetes at diagnosis of their breast cancer, 186 (2.2 percent) had diabetes and were not being treated with metformin and 260 (3.1 percent) were diabetic and had been treated with metformin.

The researchers found that metformin may improve the worse prognosis that is associated with diabetes, mainly in patients with primary HER2-positive and hormone receptor–positive breast cancer.

 

“We believe that for patients with diabetes and HER2-positive and hormone receptor positive disease,” explains Dr. Sonnenblick, “it is reasonable to recommend metformin treatment if patients have not already received treatment and to avoid insulin use as much as possible. From a prognostic point of view, patients with diabetes and HER2-positive as well as hormone receptor–positive disease who are treated with insulin should be considered at higher risk for recurrence."

The study findings are highlighted in the May 2017 issue of the Journal of Clinical Oncology. The international team of researchers included physicians from Belgium, Brazil, Chile, Denmark, Ireland, Israel, Italy, Japan, Slovenia, Switzerland, the Netherlands, the United Kingdom, and the United States.

From 2013 to 2015, lead investigator Sonnenblick did a translational and clinical research fellowship in breast cancer at the Jules Bordet Institute in Brussels, Belgium.

Learn more about groundbreaking research at the Hadassah Medical Organization.

Related Stories

alt_text

Wednesday, Feb 19 2020

Meet Dr. Ibrahim Abu Zahira, Hadassah Pediatric Cardiologist

The young doctor rings the doorbell on Star Street in Bethlehem, hoping the parents will still go along with...

READ MORE ›
alt_text

Wednesday, Feb 19 2020

A Hadassah Cardiologist, a New Baby, and a Parking Lot

It was dark and raining hard when cardiologist Prof. Ronen Beeri parked his car and hurried toward Hadassah Hospital Ein Kerem...

READ MORE ›
alt_text

Tuesday, Feb 18 2020

Hadassah Doctor Flies to Japan to Look After Israelis with Coronavirus

At the request of the Israel Health Ministry, Hadassah Medical Organization microbiology and infectious disease specialist...

READ MORE ›
alt_text

Tuesday, Feb 18 2020

Hadassah’s Holistic Hospice: A Small Haven with a Big Heart

Guided by a holistic approach, the hospice at Hadassah Hospital Mount Scopus helps patients and their loved ones...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More